Management of the Immune Reconstitution Inflammatory Syndrome
- 3 July 2012
- journal article
- review article
- Published by Springer Nature in Current HIV/AIDS Reports
- Vol. 9 (3) , 238-250
Abstract
The immune reconstitution inflammatory syndrome (IRIS) is a frequent early complication of antiretroviral therapy (ART) in patients with advanced HIV. Because there is no confirmatory diagnostic test, the diagnosis is based on clinical presentation and exclusion of alternative causes for deterioration, such as antimicrobial drug resistance. Opportunistic infection treatment should be optimized. Mild cases may require symptomatic therapy alone or nonsteroidal anti-inflammatory drugs. Corticosteroids have been used to treat more severe cases of IRIS associated with mycobacterial and fungal infections. There is evidence from a randomized controlled trial that prednisone reduces morbidity and improves symptoms in paradoxical tuberculosis (TB)-IRIS. Neurological TB-IRIS is potentially life-threatening; high-dose corticosteroids are indicated and ART interruption should be considered if level of consciousness is depressed. When considering corticosteroid treatment clinicians should be aware of their side effects and only use them when the diagnosis of IRIS is certain. In viral forms of IRIS corticosteroids are generally avoided.Keywords
This publication has 123 references indexed in Scilit:
- Paradoxical Immune Reconstitution Inflammatory Syndrome in HIV-Infected Patients Treated With Combination Antiretroviral Therapy After AIDS-Defining Opportunistic InfectionClinical Infectious Diseases, 2011
- Cryptococcal immune reconstitution inflammatory syndrome in HIV-1-infected individuals: proposed clinical case definitionsThe Lancet Infectious Diseases, 2010
- Paucity of Initial Cerebrospinal Fluid Inflammation in Cryptococcal Meningitis Is Associated with Subsequent Immune Reconstitution Inflammatory SyndromeThe Journal of Infectious Diseases, 2010
- Molecular Regulation of JC Virus Tropism: Insights into Potential Therapeutic Targets for Progressive Multifocal LeukoencephalopathyJournal of Neuroimmune Pharmacology, 2010
- Progressive multifocal leukoencephalopathy and other disorders caused by JC virus: clinical features and pathogenesisThe Lancet Neurology, 2010
- Clinical Practice Guidelines for the Management of Cryptococcal Disease: 2010 Update by the Infectious Diseases Society of AmericaClinical Infectious Diseases, 2010
- Progressive multifocal leukoencephalopathy in HIV-1 infectionThe Lancet Infectious Diseases, 2009
- Novel Relationship between Tuberculosis Immune Reconstitution Inflammatory Syndrome and Antitubercular Drug ResistanceClinical Infectious Diseases, 2009
- Tuberculosis-associated immune reconstitution inflammatory syndrome: case definitions for use in resource-limited settingsThe Lancet Infectious Diseases, 2008
- A case for treating high hepatitis B DNA levels before starting HIV therapyAIDS, 2006